Search clinical trials for: MDS

Total 1441 results

Heinrich-Heine University, Duesseldorf
Celgene Corporation; Koordinierungszentrum für Klinische Studien Düsseldorf

Active, not recruiting

IDH2-Post-Allo-Trial for Patients With IDH2-mut Myeloid Neoplasms After Allo-SCT

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute | Chronic Myelomonocytic Leukemia | IDH2 Gene Mutation | IDH2 R172 | IDH2 R140

Germany
Randy Windreich

Completed

Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS

Acute Myeloid Leukemia (AML) | Myelodysplastic Syndrome (MDS) | Hematopoietic Stem Cell Transplant (HSCT)

United States
M.D. Anderson Cancer Center
Bristol-Myers Squibb

Completed

Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Polycythemia Vera | Myelofibrosis | Leukemia, Myelomonocytic, Chronic | Hypereosinophilic Syndrome | Mastocytosis | Agnogenic Myeloid Metaplasia

United States
University of Louisville
MDS Pharma Services

Completed

TheraSphere HUD For Treatment of Unresectable Hepatocellular Carcinoma (HCC) (TheraSphere)

Hepatocellular Carcinoma

United States
Pfizer

Completed

Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML

Acute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome

Spain, Canada, Austria, Czechia, France, Hungary, Italy, Japan, Mexico, Poland, United Kingdom
Aptose Biosciences Inc.

Active, not recruiting

A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS

Acute Myeloid Leukemia | Myelodysplastic Syndromes

United States
SCRI Development Innovations, LLC
Bristol-Myers Squibb

Withdrawn

Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant Cyclophosphamide

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute | Myelodysplastic Syndrome Acute Myeloid Leukemia

United States
Celgene
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway...

Active, not recruiting

A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve (COMMANDS)

Myelodysplastic Syndromes

United States, Australia, Austria, Belgium, Canada, Czechia, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Lithuania, Netherlands, Poland, Portugal, Russian Federation, Spain, Sweden, Switzerland, Taiwan, Turke... and more
M.D. Anderson Cancer Center
Incyte Corporation

Completed

Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Leukemia

United States
Sawa Ito, MD
Horizon Pharma USA, Inc.

Completed

IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation

Myelodysplastic Syndromes | Myeloid Leukemia | Allogeneic Stem Cell Transplantation

United States
Sheba Medical Center

Completed

Phase 3 Multicenter Randomized Double Blind Placebo Controlled Study With Antibacterial Prophylaxis in Azacitidine Treated MDS Patients

Prevention

Israel
Ciceri Fabio

Completed

Phase II Trial in Elderly Patients With AML or MDS in Complete Remission Not Eligible for Allogenic Transplant (FLAT-Auto)

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Transplant-Related Hematologic Malignancy

Italy
University of Florida

Active, not recruiting

Comparing Two Diets in Patients Undergoing HSCT or Remission Induction Chemo for Acute Leukemia and MDS (UF-BMT-LDND-101)

Myelodysplastic Syndromes | Leukemia

United States
National Heart, Lung, and Blood Institute (NHLBI)

Completed

A Pilot Study of a Thrombopoietin-Receptor Agonist, Eltrombopag, in Patients With Low to Int-2 Risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndromes | Thrombocytopenia

United States
Case Comprehensive Cancer Center

Active, not recruiting

CPX-351 as a Novel Approach for the Treatment of Older Patients With AML and MDS

Myelodysplastic Syndromes | Refractory Acute Myeloid Leukemia | Relapsed Acute Myelomonocytic Leukemia

United States
Sumitomo Pharma America, Inc.

Terminated

A Phase 1b/2 Study of Alvocidib Plus Decitabine or Azacitidine in Patients With MDS

Myelodysplastic Syndromes (MDS)

United States
Ministry of Health, Bahrain

Terminated

Remineralization Agents for the Treatment of White Spot Lesions

White Spot Lesion of Tooth

Bahrain
Sumitomo Pharma America, Inc.

Terminated

A Study of TP-0184 to Treat Anemia in Adults With IPSS-R Low or Intermediate Risk MDS

Anemia in Myelodysplastic Syndromes

United States
Masonic Cancer Center, University of Minnesota
Incyte Corporation

Completed

Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Myeloid and Monocytic Leukemia

United States
Masonic Cancer Center, University of Minnesota

Completed

Relapse Prophylaxis With N-803 for AML and MDS Pts Following Allo HSCT

Myelodysplastic Syndrome (MDS) | Acute Myelogenous Leukemia (AML)

United States
Ossium Health, Inc.
Center for International Blood and Marrow Transplant Research

Withdrawn

Cryopreserved MMUD BM With PTCy for Hematologic Malignancies

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Acute Leukemia | Acute Lymphocytic Leukemia | T-lymphoblastic Lymphoma | Acute Undifferentiated Leukemia | Acute Biphenotypic Leukemia
Universitätsklinikum Hamburg-Eppendorf

Completed

5-azacytidine Treatment Versus 5-azacytidine Followed by Allogeneic Stem Cell Transplantation in Elderly Patients With Myelodysplastic Syndrome (MDS)

Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome

Germany
New York Medical College

Completed

SCT Plus Immune Therapy in Average Risk AML/MDS

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
New York Medical College

Completed

Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDS

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
Duke University

Completed

Secondary Prevention of Osteoporotic Fractures in Residents of Long-Term Care Facilities

Hip Fractures | Osteoporosis

United States
Michael Pulsipher, MD
Children's Hospital of Philadelphia; Medical College of Wisconsin; University... and other collaborators

Enrolling by invitation

KIR Favorable Mismatched Haplo Transplant and KIR Polymorphism in ALL/AML/MDS Allo-HCT Children

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Acute Lymphoblastic Leukemia

United States
Asan Medical Center

Active, not recruiting

CyFluATG in Lower Risk MDS

Myelodysplastic Syndromes

Korea, Republic of
Asan Medical Center

Active, not recruiting

HCT With PTCy in Higher-risk MDS

Patients With MDS, Acute Myeloid Leukemia (AML) Evolving From MDS, and Chronic Myelomonocytic Leukemia (CMML)

Korea, Republic of
Asan Medical Center

Completed

Hematopoietic Cell Transplantation With Post-transplantation Cyclophosphamide in MDS

Myelodysplastic Syndromes

Korea, Republic of
Eli Lilly and Company

Completed

A Study of Lebrikizumab (LY3650150) on Vaccine Response in Adults With Atopic Dermatitis (ADopt-VA)

Atopic Dermatitis

United States
Nanexa AB
Uppsala University

Completed

Pharmacokinetics, Tolerability and Safety of NEX-18a

Myelodysplastic Syndromes (MDS) | Acute Myeloid Leukemia (AML) | Chronic Myelomonocytic Leukemia (CMML)

Sweden
Astellas Pharma Global Development, Inc.

Completed

A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome | Acute Myeloid Leukemia (AML)

United States, Japan
Celgene

Active, not recruiting

A Study to Evaluate the Efficacy, Drug Levels and Safety of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in Chinese and Japanese Participants With Ring Sideroblasts Who Require Red Blood Cell Transfusions

Myelodysplastic Syndromes

China, Japan
The University of Hong Kong

Completed

The Oral Biomechanical Functions of Hong Kong Healthy Adults (HOE)

Oral Manifestations

Hong Kong
Institut de Recherches Internationales Servier
Celgene Corporation

Active, not recruiting

Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation

Untreated AML | Newly Diagnosed Acute Myeloid Leukemia (AML) | AML Arising From Myelodysplastic Syndrome (MDS) | AML Arising From Antecedent Hematologic Disorder (AHD) | AML Arising After Exposure to Genotoxic Injury

United States, Germany, Netherlands
Bellicum Pharmaceuticals

Terminated

Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Uveal Melanoma

United States
Fondazione Policlinico Universitario Agostino Gemelli...
Ministry of Health, Italy

Terminated

Haploidentical Stem Cell Transplant With or Without NK Cell Infusion in AML and MDS (Bigeminy)

Acute Myeloid Leukemia | Myelodysplasia

Italy
Race Oncology Ltd
Astex Pharmaceuticals, Inc.

Withdrawn

A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With Extramedullary AML and MDS (BISECT)

Acute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Higher Risk Myelodysplastic Syndrome

Australia
Novartis Pharmaceuticals

Completed

Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS

Myelodysplastic Syndromes | Bone Marrow Diseases | Hematologic Diseases | Leukemia | Leukemia, Myeloid | Leukemia, Myeloid, Acute | Preleukemia | Chronic Myelomonocytic Leukemia

United States, France, Australia, Netherlands, Spain, Germany, United Kingdom, Finland
Bellicum Pharmaceuticals

Terminated

Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS (THRIVE)

Acute Myeloid Leukemia | Myelodysplastic Syndromes

United States
Ain Shams University

Completed

Differences Between Patients With Vascular Parkinsonism and Parkinson's Disease

Parkinson's Disease | Vascular Parkinsonism

Egypt
Masonic Cancer Center, University of Minnesota

Completed

Allo HSCT Using RIC for Hematological Diseases

Follicular Lymphoma | Myelodysplastic Syndromes | Multiple Myeloma | Non-Hodgkin's Lymphoma | Lymphoblastic Lymphoma | Chronic Lymphocytic Leukemia | Lymphoplasmacytic Lymphoma | Acute Lymphocytic Leukemia | Acute Myelogenous Leukemia | Mantle-Cell Lymphoma | Chronic Myelogenous Leukemia | Prolymphocytic Leukemia and other conditions

United States
Federal University of Health Science of Porto Alegre

Completed

Leap Motion Controller on the Functionality of Upper Limbs in Parkinson's Disease

Parkinson Disease | Upper Extremity Dysfunction | Therapy-Related MDS

Brazil
Stanford University
Notable Labs Inc.

Active, not recruiting

Biologically Focused Therapy of Treatment-Refractory MDS Patients

Myelodysplastic Syndromes

United States
Astex Pharmaceuticals, Inc.

Completed

Study of ASTX727 vs IV Decitabine in MDS, CMML, and AML

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia

United States, Canada, Spain, Hungary, Austria, Czechia, France, Germany, Italy, United Kingdom
Zogenix MDS, Inc.
Zogenix, Inc.

Withdrawn

A Study of the Efficacy and Safety of MT1621 in Thymidine Kinase 2 (TK2) Deficiency (Treatment naïve)

Thymidine Kinase 2 Deficiency
Zogenix MDS, Inc.
Zogenix, Inc.

Completed

A Retrospective Study of Subjects With Thymidine Kinase 2 Deficiency

Thymidine Kinase 2 Deficiency

Spain, United States, Russian Federation, Turkey
Zogenix MDS, Inc.

Completed

A RETROspective Study of Patients With TK2d (RETRO)

Thymidine Kinase 2 (TK2)

United States, Spain, Israel
St. Jude Children's Research Hospital

Active, not recruiting

CD123-Directed Autologous T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)

B-ALL | T-ALL | AML/MDS | BPDCN

United States
University Hospital, Toulouse

Completed

PDL-1 Expression on Circulating Tumor Cells in Non-small Cell Lung Cancer (IMMUNO-PREDICT)

Lung Cancer

France

Search clinical trials for: MDS

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Nigeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations